Chronic idiopathic constipation (CIC) affects 35 million adults in the United States, making it one of the most common gastrointestinal disorders. Despite the high prevalence, CIC is often underdiagnosed and undertreated, which exacts a functional, psychosocial, and economic toll on patients and their loved ones. The current treatment goal in CIC is multi-symptom relief, but only 16% of patients with CIC are on prescription therapy, and they often only obtain partial relief, with many using laxatives on a regular basis without medical supervision.
This CME Outfitters OnDemand features evidence-based dialogue that focuses on guideline recommendations for diagnosing patients with CIC, assessing the efficacy and safety of novel pharmacotherapeutic options, and implementing strategies for multidisciplinary collaboration, with the goal of providing full relief to patients with CIC.
At the end of this CME/CE activity, participants should be able to:
The following learning objectives pertain only to those requesting CNE or CPE credit:
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Gastroenterologists, PAs, nurse practitioners, nurses, and pharmacists.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Lembo reports that he receives research support from: Ironwood Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Vanda Pharmaceuticals Inc. He is on the advisory committee for Cara Care. He is a consultant for Ardelyx; Ironwood Pharmaceuticals, Inc; Mylan; Salix Pharmaceuticals; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and Vibrant Pharma Inc.
Dr. Chey reports that he receives grants and research support from Biomerica, Inc.; Commonwealth Diagnostics International, Inc.; QOL Medical; Urovant Sciences, Inc.; Vibrant Pharma Inc.; and Zespri. He is a consultant for AbbVie Inc./Allergan; Alnylam Pharmaceuticals Inc.; Arena Pharmaceuticals, Inc.; Biomerica, Inc.; Gemelli Biotech; IM Health; Ironwood Pharmaceuticals, Inc.; Phathom Pharmaceuticals; Progenity, Inc.; QOL Medical; RedHill Biopharma Inc.; Ritter Pharmaceuticals Inc.; Salix Pharmaceuticals/Valeant Pharmaceuticals; Urovant Sciences, Inc.; and Vibrant Pharma Inc. He is a stock shareholder (directly purchased) for Options: GI OnDEMAND; ModifyHealth, LLC; and Ritter Pharmaceuticals Inc.
Dr. Drossman has no disclosures to report.
Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Olga Askinazi, PhD (planning committee) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-20-111-H01-P.
Call us at 877.CME.PROS (877.263.7767).